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Dietary interventions like gluten-free and casein-free diets have been reported to improve intestinal, autoimmune and neurological symptoms in patients
with a variety of conditions; however, the underlying mechanism of benefit for such diets remains unclear. Epigenetic programming, including CpG methylation
and histone modifications, occurring during early postnatal development can influence the risk of disease in later life, and such programming may be modulated
by nutritional factors such as milk and wheat, especially during the transition from a solely milk-based diet to one that includes other forms of nutrition. The
hydrolytic digestion of casein (a major milk protein) and gliadin (a wheat-derived protein) releases peptides with opioid activity, and in the present study, we
demonstrate that these food-derived proline-rich opioid peptides modulate cysteine uptake in cultured human neuronal and gastrointestinal (GI) epithelial cells
via activation of opioid receptors. Decreases in cysteine uptake were associated with changes in the intracellular antioxidant glutathione and the methyl donor S-
adenosylmethionine. Bovine and human casein-derived opioid peptides increased genome-wide DNA methylation in the transcription start site region with a
potency order similar to their inhibition of cysteine uptake. Altered expression of genes involved in redox and methylation homeostasis was also observed. These
results illustrate the potential of milk- and wheat-derived peptides to exert antioxidant and epigenetic changes that may be particularly important during the
postnatal transition from placental to GI nutrition. Differences between peptides derived from human and bovine milk may contribute to developmental
differences between breastfed and formula-fed infants. Restricted antioxidant capacity, caused by wheat- and milk-derived opioid peptides, may predispose
susceptible individuals to inflammation and systemic oxidation, partly explaining the benefits of gluten-free or casein-free diets.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Keywords: Glutathione; Casomorphin; Gliadin; Autism spectrum disorder; Schizophrenia; Celiac disease; Gluten-free/casein-free diet1. Introduction
Gluten-free or casein-free diets have been reported to improve
intestinal, autoimmune and neurological symptoms in celiac disease
[1,2], autism [3,4] and schizophrenia [5,6], but the underlying
mechanism of benefit for such diets remains unclear. Emerging
evidence from biochemical investigations indicate that neurological
disorders like schizophrenia and autism spectrum disorder (ASD)
might have underlying defects in prenatal and early postnatal
neurodevelopment as a contributing factor to the etiology of these
disorders. Especially, systemic oxidative stress has been strongly☆ Funding source: This work was supported by research grants to R.D.
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significantly lower levels of the antioxidant glutathione (GSH), whose
synthesis is limited by cysteine availability. Consistently, brain GSH
levels are also reported to be decreased in autism [9] and
schizophrenia [10], strongly supporting the proposal that a deficit in
this specific antioxidant, namely GSH, might contribute to neurodeve-
lopmental and neuropsychiatric disorders. Notably, intestinal mucosa
and plasma levels of GSH are also reduced in pediatric celiac disease
patients [11]. Moreover, in few cases, patients with neurological
conditions [12] like autism [13] and schizophrenia [14] also report a
co-morbid problem of celiac disease and/or gut inflammation.
Oxidative stress and DNA methylation changes are metaboli-
cally coupled via the transsulfuration pathway and one-carbon
metabolism. DNA methylation is carried out by a class of enzymes
called DNA methyltransferases DNMTs, which depend on the levels
of S-adenosylmethionine (SAM) [15], which in turn are dependent on
the action of the enzyme methionine synthase (MS) and the redox
status of the cell [16]. SAMacts amethyl donor for over 200methylation
reactions and is converted to S-adenosylhomocysteine (SAH), an
inhibitor of methylation reactions. Hence, the ratio SAM/SAH is termed
as the methylation capacity of the cell. Several studies report decreasedr the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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schizophrenia. DNA methylation is an important methylation reaction,
involving addition of a methyl groups at CpG sites on DNA, and it is a
major factor for epigenetic-based changes in gene expression. In recent
studies, abnormal DNA methylation patterns have been implicated in
schizophrenia [17,18] and ASD [19,20], but more prominently in the
latter. Rett syndrome, immunodeficiency, centromeric instability, facial
anomalies (ICF) syndrome and autosomal dominant cerebellar ataxia
are few examples of a heterogeneous group of neurodegenerative and
neurodevelopmental disorders caused by changes in proteins that
either “read” or “write” DNA methylation, resulting in disordered DNA
methylation at numerous single-copy genes as well as in specific
sequences of repeat DNA in parts of constitutive heterochromatin [17].
Similarly, deficiency of B vitamins, methionine, folic acid and/or choline
can significantly alter DNA methylation by affecting levels of SAM and
SAH [21,22]. However, while these studies indicate the interaction
between nutrients and the pathways regulating DNA methylation, it is
still unclear how a specific gene is targeted by nutrients or alternatively,
if these changes are stochastic in nature [21,23].
Epigenetic programming during early postnatal development can
influence lifelong disease risk [24,25] and may be modulated by
nutritional factors, especially factors affecting DNA methylation
[26,27]. Milk (either human or bovine) or milk-derived products
may be the only source of nutrition for infants during early postnatal
development, while wheat-containing foods are commonly intro-
duced after the first year. Casein is an important milk protein, and
similarly gliadin is a wheat gluten-derived protein, and hydrolytic
digestion of both releases peptides with opioid activity [28,29].
Enzymatic digestion of human β-casein liberates the heptapeptide
hβ-casomorphin-7 (YPFVEPL), designated hBCM7, while bovine β-
casein yields bβ-casomorphin-7 (YPFPGPL; bBCM7), and α-gliadin
yields gliadinomorphin-7 (YPQPQPF; GM7) (Fig. 1a). Divergent
amino acids at positions 3–5 result in distinctive conformations, and
the presence of 2 or 3 proline residues makes these peptides
resistant to further proteolysis [30]. Each of these homologous
proline-rich peptides has the capacity to activate opioid receptors
[28–31].
Endogenous opioid peptides normally found in the body are called
endorphins (e.g., β-endorphins, enkephalins), whereas exogenous
opioid peptides (e.g., morphine, hBCM7, bBCM7 and GM7) are called
exorphins. Low energy conformations of the food-derived exorphins
bear a structural similarity to morphine (Supplementary Fig. 1),
particularly at their N-terminal tyrosine residue, which is also a
feature of endorphins and is critical for their affinity and efficacy at
opioid receptors [32]. Studies show that morphine-induced activation
of μ-opioid receptors induces changes in the expression of EAAT3,
which provides the primary pathway for cysteine uptake in both
mature neurons [33,34] and GI epithelial cells [33,35], particularly in
the distal ileum [35]. Morphine can induce oxidative stress and cause
a pro-oxidant shift in cell redox status [36–38], which subsequently
can cause a decrease in the availability of SAM for more than 200
methylation reactions, including DNA methylation, resulting in
subsequent transcriptional changes. Hence, the current study inves-
tigated whether morphine and food-derived opioid peptides can
induce alterations in cellular redox status, DNA methylation [39] and
transcription by altering cysteine uptake in SH-SY5Y cells, providing
biochemical evidence that could potentially support the use of
nutritional intervention, i.e., a gluten-free/casein-free diet.
2. Materials and methods
2.1. Materials
Minimum essential medium, α-modification (α-MEM), trypsin, Hank's balanced
salt solution (HBSS) and penicillin/streptomycin/fungizone antibiotic solution were
purchased from Mediatech (Manassas, VA, USA). Fetal bovine serum (FBS) wasobtained from Hyclone (Logan, UT, USA). [35S]-Cysteine was purchased from American
Radiolabeled Chemicals (St. Louis, MO, USA). Morphine and other drugs were obtained
from Sigma Chemicals (St. Louis, MO, USA). Human and bovine forms of BCM-7, as well
as gliadin-7 peptide, were custom synthesized by Neopeptide (Cambridge, MA, USA).
2.2. Cell culture
Monolayers of cells were grown in 10-cm tissue culture dishes with 10 ml of α-
MEM supplemented with 1% penicillin/streptomycin/fungizone and 10% FBS, in 5% CO2
at 37°C. For most experiments, cells were plated and incubated for 48 h prior to use.
2.3. Cysteine uptake
The cysteine uptake assaywas performed according to amethoddescribed previously
[39]. In brief, SH-SY5Y human neuroblastoma cells plated in six-well plates were
pretreated with drugs and incubated for various times prior to measuring uptake. Media
was aspirated and cells were washed with 600 μl of HBSS at 37°C. Non-radioactive HBSS
was aspirated, replacedwith 600 μl of 37°CHBSS containing [35S]-cysteine (1 μCi/1ml), 10
μM unlabelled cysteine and 100 μM DTT, and cells were incubated for 5 min. The [35S]-
cysteine/HBSSmixture was aspirated and treatmentwas terminated by twowashes with
ice-cold HBSS. Cells were then lysed with 600 μl of dH2O, scraped, collected in 1.5 ml
microcentrifuge tubes and sonicated for 10 s. One-hundredmicroliters of each samplewas
aliquoted for protein assay. Two-hundred microliters of each sample (in triplicate) was
aliquoted into scintillation vials with 4 ml of scintillation fluid, vortexed and counted for
radioactivity, normalized against protein content.
2.4. Thiol metabolite assay
SH-SY5Y neuroblastoma cells were grown to confluence in α-MEM. Media was
aspirated and the cells werewashed twicewith 1ml of ice-coldHBSS. HBSSwas aspirated
and0.6ml ice-colddH2Owas added to the cells. Cellswere scraped fromthe flask/dish and
suspended in dH2O. The cell suspensionwas sonicated for 15 s on ice and 100 μl was used
to determine protein content. The remaining lysate was added to a microcentrifuge tube
andanequal volumeof0.4Nperchloricacidwas added, followedby incubationon ice for 5
min. Samples were centrifuged at 5000g and the supernatant was transferred to new
microcentrifuge tubes. One-hundred microliters of sample was added to a conical
microautosampler vial and kept at 4°C in the autosampler cooling tray. Tenmicroliters of
this sample was injected into the HPLC system.
The separation of redox andmethylation pathwaymetaboliteswas accomplished using
an Agilent Eclipse XDB-C8 analytical column (3×150 mm; 3.5 μm) and an Agilent Eclipse
XDB-C8 (4.6×12.5mm;5 μm)guard column. Twomobilephaseswereused:Mobile PhaseA
was 0% acetonitrile, 25 mM sodium phosphate and 1.4 mM 1-octanesulfonic acid, adjusted
to pH 2.65 with phosphoric acid. Mobile Phase B was 50% acetonitrile. The flow rate was
initially set at 0.6ml/min and a step gradientwas used: 0–9min, 0%B; 9–19min, 50% B; 19–
30min, 50% B. The columnwas then equilibratedwith 5% B for 12min prior to the next run.
Temperature was maintained at 27°C. The electrochemical detector was an ESA CoulArray
with BDD Analytical Cell Model 5040 and the operating potential was set at 1500 mV.
Sample concentrationswere determined from the peak areas ofmetabolites using standard
calibration curves and ESA-supplied HPLC software. Sample concentrations were
normalized against protein content. In some cases, samples were diluted in mobile phase
as needed or up to 50 μl of sample was injected to assure that thiol levels were within the
range of the standard curve.
2.5. DNA methylation analysis
Genomic DNA was extracted from samples with the Easy DNA Kit (Invitrogen
K1800-01) using the appropriate protocol for cell lines. For a full overview of the
MethylCap-Seq protocol, refer to De Meyer et al. [40]. In summary, fragmentation was
performed on Covaris S2 with the following settings: duty cycle, 10%; intensity, 5;
cycles per burst during 200 s, 200; to obtain fragments with an average length of 200
bp. The powermode is frequency sweeping, temperature is 6–8°C andwater level is 12.
A maximum of 5 μg is loaded in 130 μl Tris–EDTA in a microtube with AFA intensifier.
For samples with less DNA input (down to 500 ng), we dilute the DNA in 1:5 diluted
Tris–EDTA. DNA with an input from 5 to 3 μg is analyzed on the Agilent 2100 on a DNA
1000 chip. DNA with an input lower than 3 μg is concentrated in a rotary evaporator to
25 μl and the fragment distribution is checked on a high-sensitivity DNA chip.
Methylated DNA was captured using the MethylCap kit (Diagenode, Belgium),
according to the manufacturer's protocol; starting concentration was 200 ng. The
yield was typically between 0.5 and 8 ng total captured DNA. Fragments were
subsequently sequenced using the Illumina Genome Analyzer II. The concentrations of
fragmented and captured DNA were determined on a Fluostar Optima plate reader
with the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen P7589) at 480/520 nm.
To prepare the DNA library, we used the DNA Sample Prep Master Mix Set 1 (NEB
E6040) in combination with the Multiplexing Sample Preparation Oligo Kit (96
samples, Illumina PE-400-1001). We use the entire fragmented DNA and followed the
NEB protocols. NEBNext End Repair Module Protocol is to purify with a Qiaquick PCR
Purification Kit (Qiagen 28104) and elute in 37 μl Elution Buffer (EB). NEBNext dA-
tailing Module Protocol is to purify on a minelute PCR Purification Kit (Qiagen 28004)
and elute in 25 μl EB. NEBNext Quick LigationModule Protocol is to purify on aminelute
Fig. 1. Food-derived opioid peptides and morphine inhibit cysteine uptake in SH-SY5Y cells. (a) β-Casein from milk and α-gliadin from wheat, barley and rye are hydrolysed in the
intestine by pepsin, leucine aminopeptidase and elastase to release peptides with opioid activity. The 7-aa proline-containing peptides from human and bovine milk, and that from
wheat, have homologous sequences, including two or three proline residues. (b) Radiolabeled cysteine uptake in SH-SY5Y human neuroblastoma and (c) Caco2 colon carcinoma cell
lines in the presence of increasing concentrations (0.1 nM to 1 μM) of morphine or opioid peptides. Cells were treated for 30 min. (d) Time-dependent effects of opioid peptides and
morphine on cysteine uptake by SH-SY5Y cells. SH-SY5Y cells were treated with 1 μM of morphine or opioid peptides for 0.5, 4, 24 and 48 h (n=6). *Pb.05 and **Pb.01 vs. control.
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sequencing adapters provided in the Multiplexing Sample Preparation Oligo Kit. Size
selection of the library was done on a 2% agarose gel (Low Range Ultra Agarose Biorad
161-3107). We used a 1-Kb Plus ladder (Invitrogen 10787-018) and ran the gel at 120
V for 2 h. A fragment of 300±50 bp was excised and eluted on a Qiagen Gel Extraction
Kit column (Qiagen 28704) and eluted in 23 μl EB.We followed the Illumina library amplification index protocol with the following
alterations: We used 22 μl DNA and performed 21 cycles. The sample was purified on a
Qiaquick PCR Purification column (Qiagen 28101) and eluted in 50 μl EB, 1:5 diluted
and concentrated in a rotary evaporator to 10 μl, and 1 μl was applied to a Agilent 2100
HS DNA chip and the concentration was determined by smear analysis on the Agilent
2100. The samples were diluted to 10 nM. After denaturation with NaOH, we diluted
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Station User Guide. Sequencing was performed according to the HiSeq user guide
(performing a Multiplexed PE Run), with 2×51 cycles for the paired-end runs.
2.6. Statistical methods
Statistical analyses were carried out using GraphPad Prism version 5.01. Student's
t test for independent means was used to test for significant differences between control
and experimental groups. Data were expressed as mean±standard error of the mean.
Best-fit values were calculated using nonlinear and linear regression models. Nonlinear
regressions used a two-phase exponential decay function. Comparisons betweenmultiple
groups of data were conducted using one-way analysis of variance, and Tukey's post hoc
test was used to determine the differences between individual groups.
3. Results
Wepreviously characterized EAAT3 expression in SH-SY5Y human
neuroblastoma cells and indicated that it makes a major (N90%)
contribution to [35S]-cysteine uptake [39]. To investigate whether
morphine and opioid peptides could alter EAAT3 activity via μ-opioid
receptors, we carried out a radiolabeled [35S]-cysteine uptake assay in
SH-SY5Y cells. Pretreatment of SH-SY5Y human neuroblastoma cells
with either morphine or casein/gluten-derived exorphin peptides
for 30 min inhibited the uptake of radiolabeled [35S]-cysteine in a
concentration-dependent manner, with an efficacy order ofFig. 2. Effect of opioids on GSH/GSSG and SAM/SAH ratios. Ratios for (a) GSH/GSSG and (b) SAM
24 h, at a concentration of 1 μM (n=4). *Pb.05 and **Pb.01 vs. control.morphineNbBCM7NhBCM7NGM7 and IC50 values of 0.16, 1.31, 4.34
and 1.94 nM, respectively (Fig. 1b). Morphine and exorphin peptides
inhibited cysteine uptake with similar efficacy but lower potency in
Caco2 cells, a cell line derived from humanGI epithelial cells, with IC50
values of 6.38, 15.95, 90.08 and 301 nM, respectively (Fig. 1c).
Inhibition of cysteine uptake was fully developed at 30 min and was
sustained through 48 h of morphine or exorphin exposure, although
the extent of inhibition was modestly decreased in a time-dependent
manner. Inhibition by bBCM7 was greater than that of hBCM7 at 4, 24
and 48 h (Fig. 1d). Cysteine uptake effects of morphine and exorphin
peptides were blocked by naltrexone, an antagonist of both μ- and
delta-opioid receptors (Supplementary Fig. 2), as well as by D-Phe-
Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr (CTAP), a selective μ-antagonist, but
not by the delta antagonist naltrindole (NTI) (Supplementary Fig. 3).
As mentioned previously, cysteine is the rate-limiting precursor for
GSH synthesis. Other source of cysteine involves the transsulfuration
pathway via homocysteine (HCY). However, in neuronal cells, this
pathway is partially blocked, which emphasizes the role of EAAT3-
mediated cysteine uptake for GSH homeostasis. HCY can also be
converted to methionine via the activity of MS. To investigate whether
decreases in cysteine uptake translate into changes in metabolic
intermediates involved in transsulfuration andmethioninemethylation
cycle pathways, as illustrated in Supplementary Fig. 4, we measured/SAH were calculated after treatment with opioid peptides andmorphine for 0.5, 4 and
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peptides for different times.Morphineandopioidpeptides caused time-
dependent decreases in cysteine, GSH and methionine, while HCY and
cystathionine levels increased (Supplementary Fig. 5). These changes
are consistent with decreased GSH synthesis, decreased activity of MS
and increased transsulfuration of HCY to cystathionine.
Redox status is reflected by the ratio of reduced GSH to oxidized
GSSG (GSH/GSSG), whereas the ratio of SAM to SAH (SAM/SAH)
reflects methylation capacity. Morphine and exorphin peptides
caused progressive decreases in GSH/GSSG, reaching more than 3-
fold at 24 h (Pb.01, Fig. 2a). Morphine, bBCM7 and GM7, but not
hBCM7, transiently decreased SAM/SAH, with a 2–3-fold reduction of
SAM/SAH levels observed with morphine, bBCM7 and GM7 treatments
at 24 h (Pb.01, Fig. 2b). Thus, the decrease in cysteine uptake caused by
morphine and opioid peptides translates into downstream changes
affecting redox status and methylation capacity in SH-SY5Y cells.
DNAmethylation is an important reaction, representing one of the
key mechanisms for epigenetic regulation of gene expression, which
has particular significance for postnatal development. We used
methyl-CpG binding domain (MBD) protein-enriched genome se-
quencing (MBD-seq) to evaluate the influence of bBCM7 and hBCM7
on global DNA methylation status in SH-SY5Y cells, compared to the
effect of morphine. To evaluate DNA methylation status in the
promoter region, 53,561 genes were aligned at their transcription
start site (TSS) and the level of methylation was calculated for 3000
bp in either direction, as normalized to the level at the beginning of
the region (−3000 bp). As previously described for brain frontal
cortex [41], the most prominent feature in the resulting methylation
density landscape was an asymmetric peak occurring at about +80
bp, flanked by less methylated valley regions (Fig. 3). A 4-h treatment
with morphine or milk-derived opioid peptides (1 μM) caused a
significant shift toward increased methylation (i.e., promoter hyper-
methylation) in the immediate TSS region. Morphine was most
effective, increasing genome-wide methylation at the TSS peak to 22%
above control levels, followed by bBCM7 and hBCM7, representing
increases of 17% and 10%, respectively, a rank order that mirrors their
inhibition of cysteine uptake. Morphine treatment significantly
altered methylation status of a total of 5366 genes in this TSS region,
bBCM7 3891 and hBCM7 1627 (Pb.05). Thus, opioid-induced changesFig. 3. Morphine andmilk-derived opioid peptides increase genome-wide promotermethylatio
genome-wide DNA methylation was analyzed by MBD-seq. We aligned 53,561 genes at their
normalized to values at−3000 bp. Inset: Methylation of all genes was evaluated at the+80 bp
values for morphine, bBCM7 and hBCM7 of 1.8e-25, 0.016 and 3.2e-40, respectively.in cysteine uptake, redox status as well as the SAM/SAH ratios, are
associated with significant genome-wide changes in DNA methyla-
tion levels at the TSS.
We have previously showed changes in transcription of a panel of
11 redox and methylation pathway genes in association with
decreased EAAT3-mediated cysteine uptake in response to the
oligomeric Aβ amyloid peptide, implicated in causation of Alzheimer's
disease [39]. Hence, we wanted to investigate whether morphine and
opioid peptides could induce similar changes in the transcriptional
levels of these genes. For this purpose, we used qRT-PCR to evaluate
changes in mRNA expression levels after treatment of SH-SY5Y cells
with morphine or opioid peptides (4 h, 1 μM). hBCM7 significantly
increased expression of nine genes in the panel, including EAAT3,
GCLC, GCLM, CGL, CBS, MTR, MAT2A, DRD4 and LINE-1 (Fig. 4). In
contrast, morphine and bBCM7 decreased the expression of these
genes (with the exception of GCLM), while GM7 produced a mixed
pattern of increased and decreased gene expression. Thus, food-
derived opioid peptides affect redox/methylation gene expression,
with hBCM7 and bBCM7 showing opposite effects. These results
indicate that morphine and food-derived opioid peptides induce
changes in the redox and methylation capacity of the cells by
modulating cysteine uptake via EAAT3 and subsequent changes in
DNA methylation and gene expression levels were observed. However,
the changes in the DNA methylation status might not be directly
responsible for changes in the transcriptional status of genes involved in
the regulation of redox and methylation pathways, and other mecha-
nisms might be involved in regulating mRNA levels (e.g., transcription
factors or mRNA stability).
4. Discussion
Food-derived opioid peptides are produced in the gut, where
they can exert effects on the gut intestinal epithelium, but they can
also enter the systemic circulation [42] and may be able to cross the
blood–brain barrier [43]. Recently, it has also been revealed that
casein-derived opioid peptides are present in the urine of autistic
and schizophrenic subjects, but not of controls [44,45]. It has been
suggested that increased blood levels of bBCM7, in conjunction with
lower activity of dipeptidylpeptidase IV, the enzyme responsible forn. SH-SY5Y cells were treated with 1 μMmorphine, bBCM7 or hBCM7 for 4 h (n=5), and
TSS, and average methylation between −3000 bp and +3000 bp was computed and
peak for each group and expressed as a percentage of the control group level, yielding P-
Fig. 4. Morphine and opioid peptides alter redox/methylation gene expression. SH-SY5Y cells were treated with opioid peptides or morphine (1 μM) for 4 h, RNA was isolated and
mRNA levels were probed by qRT-PCR with primers designed for a panel of redox and methylation-linked genes. Values were normalized to β-actin levels and to control gene
expression (n=4). The y-axis indicates fold changes in mRNA levels. Asterisk (*) indicates significant difference (Pb.05) from untreated control cells.
Fig. 5. Summarydiagramof redox-dependent epigenetic regulation by μ-opioid receptors.
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syndrome [45], reflecting μ-receptor-mediated respiratory depres-
sion. The current study supports previous results indicating the
biochemical effects of the food-derived peptides specifically on the
μ-opioid receptor.
Intolerance to casein or gliadin can contribute to inflammation of
the gastrointestinal (GI) tract as exemplified by celiac disease, as well
as systemic effects including neurological manifestations. While true
IgE-based allergy can be triggered by gluten in some individuals,
intolerance associatedwith actions of gluten-derived peptides such as
GM7 may affect a larger population, and there is evidence that the
number of people suffering from gluten intolerance is increasing [46].
A gluten-free diet usually relieves the symptoms of celiac disease. As
mentioned previously, plasma and brain GSH is decreased and other
thiol metabolites are abnormal in subjects suffering from autism [8],
schizophrenia [7] and celiac disease. In our study, we observed similar
pattern of decreased GSH as well as altered thiol metabolites after
exposure to morphine and opioid peptides. In light of the above-
mentioned clinical evidence and metabolic relationships, data from
the current study suggest that the salutary effects of a gluten-free/
casein-free diet might reflect actions of the opioid peptides released
from milk and wheat on biochemical pathways via modulating the
cellular redox status.
Only anecdotal evidence is available for the nutritional and dietary
interventions recommended for treatment of ASD, schizophrenia and
celiac disease patients, and supporting mechanistic or biochemical
investigation is rarely performed. The current study is the first to
describe the ability of food-derived opioid peptides and morphine to
modulate cysteine uptake, with subsequent effects on cellular redox
and methylation status leading to global changes in DNA methylation
and gene transcription. As summarized in Fig. 5, these actions
constitute a biochemical pathway, namely a redox/methylation
signaling pathway, which extends our current understanding of the
physiological and pharmacological effects of food-derived opioid
peptides. In individuals who are sensitive to milk or wheat, these
actions of food-derived opioid peptides may contribute to inflamma-
tion and, in the case of milk-derived hBCM7 and bBCM7, they may
influence epigenetic programming during early postnatal develop-
ment period. Systemic effects on redox, methylation and epigenetic
status could potentially result either from an inhibitory influence of
opioid peptides on cysteine absorption from the GI tract. Additionally,
distinctive epigenetic effects of hBCM7 vs. bBCM7 might also explainthe well-recognized health benefits of breast feeding vs. formula
feeding.
Changes in epigenetic marks such as DNA methylation are crucial
for adaptive changes in gene transcription and early-life experience;
for example, nutrition can influence the lifelong risk of diseases such
as cancer, type 2 diabetes mellitus, obesity, inflammation and
neurocognitive disorders [21–23,47]. Our findings provide a candi-
date mechanism by which nutritional and dietary components can
affect biochemical pathways and induce changes in epigenetic status
and subsequently modulate disease risk. Since EAAT3 is expressed in
T-cells, including T-regulatory cells [48], this novel μ-receptor-
mediated redox-based signaling pathway may also be important for
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naltrexone [49]. While the GI tract may be the primary locus for
opiate peptide effects, their influence can extend throughout the
body, by virtue of their influence over systemic antioxidant resources.
It should be noted that bovine form of BCM7 is only released from
cows with the A1 genotype and not A2 genotype cows.
While the mechanism underlying inhibition of cysteine uptake by
food-derived opiate peptides is not fully established, we previously
found that protein kinase A and/or mitogen-activated protein kinase
kinase are involved in mediating the effects of morphine on EAAT3
[50]. Their inhibitory effects on cysteine uptake are also observed at
the levels of redox status and methylation capacity as well as on DNA
methylation status and the transcription of genes involved in
maintaining the redox methylation homeostasis. However, the
current results do not propose a direct causal relationship between
the changes in DNA methylation and the resultant transcriptional
state, and several contributing factors, other than the global DNA
methylation status, might be affected by opioid peptides. Thus
changes in redox and methylation could potentially influence a
wide array of factors affecting mRNA levels, including the availability
and binding of transcriptional factors or polycomb group proteins,
histone modifications or changes in mRNA stability.
It should be noted that the current study was carried out using SH-
SY5Y and Caco2 cancer cell lines, whichmight not reflect responses in
non-transformed cells. However, these cell lines have been used
previously for epigenetic studies [50,51] and they provide a useful
preliminary indication of opiate peptide effects, which needs to be
replicated in other systems before being confidently extrapolated to
clinical manifestations. However, the current study does provide the
first mechanistic explanation through which nutritional factors might
impinge on the epigenetic and transcriptional status of genes. The
relationship between gluten- and casein-derived opiate peptide-
induced redox and methylation changes and downstream effects of
these changes still remain to be elucidated. Taken together, our
findings provide a novel antioxidant-based biochemical pathway
linking gut and brain function via the diet.
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